Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le dimanche 05.04.2020 à 10:00 AM CEST
Paramétrages

Paramétrages

1. WO2007139886 - FORMULATIONS À LIBÉRATION RETARDÉE DE CHLORHYDRATE DE DULOXÉTINE

Numéro de publication WO/2007/139886
Date de publication 06.12.2007
N° de la demande internationale PCT/US2007/012387
Date du dépôt international 22.05.2007
CIB
A61K 31/381 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
31Préparations médicinales contenant des ingrédients actifs organiques 
33Composés hétérocycliques
38ayant le soufre comme hétéro-atome d'un cycle
381ayant des cycles à cinq chaînons
A61K 9/50 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
9Préparations médicinales caractérisées par un aspect particulier
48Préparations en capsules, p.ex. de gélatine, de chocolat
50Microcapsules
CPC
A61K 31/381
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
381having five-membered rings
A61K 9/5026
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules ; having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
5005Wall or coating material
5021Organic macromolecular compounds
5026obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
A61K 9/5042
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules ; having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
5005Wall or coating material
5021Organic macromolecular compounds
5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
A61K 9/5047
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules ; having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
5005Wall or coating material
5021Organic macromolecular compounds
5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
A61K 9/5078
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules ; having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
5073having two or more different coatings optionally including drug-containing subcoatings
5078with drug-free core
Déposants
  • TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL/IL]; 5 Basel Street P.O. Box 3190 49131 Petah Tiqva, IL (AE, AG, AL, AM, AT, AU, AZ, BA, BE, BF, BG, BH, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • TEVA PHARMACEUTICALS USA, INC. [US/US]; 1090 Horsham Road P.O. Box 1090 North Wales, PA 19454-1090, US (BB)
  • KOLATKAR, Gershon [IL/IL]; IL (UsOnly)
  • ZISMAN, Erela [IL/IL]; IL (UsOnly)
Inventeurs
  • KOLATKAR, Gershon; IL
  • ZISMAN, Erela; IL
Mandataires
  • GENCARELLI, Gina, R. ; Kenyon & Kenyon LLP One Broadway New York, NY 10004-1050, US
Données relatives à la priorité
60/802,84922.05.2006US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) DULOXETINE HYDROCHLORIDE DELAYED RELEASE FORMULATIONS
(FR) FORMULATIONS À LIBÉRATION RETARDÉE DE CHLORHYDRATE DE DULOXÉTINE
Abrégé
(EN)
Delayed release formulations of duloxetine hydrochloride and methods for its manufacture are described. A preferred formulation includes an inert core, a drug layer comprising duloxetine hydrochloride, a separating layer and an enteric layer comprising at least one of methacrylic acid copolymer and hydroxypropyl methyl cellulose phthalate.
(FR)
L'invention concerne des formulations à libération retardée de chlorhydrate de duloxétine et leurs procédés d'élaboration. Une formulation préférée comprend un noyau inerte, une couche de médicament contenant du chlorhydrate de duloxétine, une couche de séparation et une couche entérique contenant un copolymère d'acide méthacrylique et/ou un phtalate d'hydroxypropyl méthylcellulose.
Autres publications associées
Dernières données bibliographiques dont dispose le Bureau international